Lipidomic Characterization in Non-metastatic Breast Cancer Women Undergoing Surgery: a Pilot Study. (BreCaLip)

Patients Age <65 years (not to have influence on functioning of desaturase enzymes that decline with older ages). Neoplastic pathology: primary invasive breast cancer or ductal in situ (DCIS) newly diagnosed, in the pre-operative phase and which has not already undergone chemo- or radiotherapy. Absence of serious intestinal and hepatic pathologies, diabetes, both insulin-dependent and in hypoglycaemic treatment or other pancreatic affection, thyroid affections in pharmacological treatment. Absence of supplementation with omega-3 based supplements for at least 6 months. Homogeneous distribution by BMI (1:1 ratio subjects with BMI≥25 and BMI<25, respectively). Informed consent to participate in the study. controls Age <65 years; Not be affected by cancer; BMI <25kg/m2; Informed consent to participate in the study Exclusion Criteria: patients Age ≥65 years (would affect the functioning of desaturase enzymes that decline with older age). Invasive primary breast cancer or ductal in situ (DCIS) previously treated with chemo- or radiotherapy. Metastasis at diagnosis. Presence of serious intestinal and hepatic pathologies. Presence of diabetes, both insulin-dependent and in hypoglycaemic treatment or other pancreatic disease, thyroid disease in pharmacological treatment. Supplementation with omega-3 based supplements for at least 6 months. Failure to sign the informed consent to participate in the study. controls Age ≥65 years; Suffering from tumor pathology; BMI ≥25kg/m2; Refusal to sign informed consent to participate in the study.